At the Virginia Tech Corporate Research Center (VTCRC), we take pride in fostering a community where innovation thrives, and our tenants continually push the boundaries of technology and science. One of our tenants, CELLINK, made headlines with its recent acquisition of in-vitro technology specialist MatTek Corporation for $68 million. This milestone not only solidifies CELLINK’s position as a leader in bioprinting but highlights exciting advancements happening at VTCRC.
Driving Innovation from Blacksburg to the World
CELLINK, a global pioneer in 3D bioprinting, has called VTCRC home as part of its expanding U.S. operations. CELLINK develops bio-inks and 3D bioprinters that enable researchers to grow human tissue models – vital for drug development and regenerative medicine. This acquisition strengthens CELLINK’s mission to reduce and eliminate the need for animal testing by providing human-derived tissue models.
A Synergy of Vision and Technology
The deal will combine CELLINK’s bioprinting technology with MatTek’s expertise in in-vitro tissue models. This merger is expected to accelerate the development of more accurate and ethical testing platforms for pharmaceuticals and cosmetics.
CELLINK’s Impact on the VTCRC Ecosystem
CELLINK’s success reflects the dynamic environment at VTCRC, where cutting-edge companies across diverse technology industries collaborate and thrive. The acquisition not only underscores CELLINK’s growth but also strengthens VTCRC as a hub for groundbreaking advancements in life sciences and technology.
Congratulations to CELLINK on this exciting next chapter! We are proud to have them as part of the VTCRC community. We look forward to the continued impact they will make in advancing healthcare and ethical research.